MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care  Fall

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care Fall

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced wound care portfolio in the exhibit hall at booth 511.

Sponsored Lunch Symposium
Title: Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape
Date: Thursday, September 4, 2025
Time: 11:40 – 1:10 p.m. PDT
Faculty: Paul Kim, DPM, MS, FACFAS; Nicolas Mouawad, MD, MPH, MBA, DFSVS, FRCS, FACS, RPVI; Scott Boynton, DPM, FACFAS
Description: Wound care is constantly evolving, and clinicians must adapt to an ever-changing landscape of patient complexities and clinical challenges. In this dynamic symposium, Drs. Paul Kim, Nicolas Mouawad, and Scott Boynton will discuss advanced treatment approaches that support clinicians in optimizing wound healing across diverse patient populations and present challenging real-world cases.

Accepted Poster Presentations
The Company is pleased to announce that six clinical and scientific posters have been accepted and will be on display in the poster hall.

  • Therapeutic Potential of Amniotic Tissue in Promoting Pigment Restoration During Wound Healing
  • Bovine Extracellular Matrix Particulate Modulates Fibroblast Cellular Activities Supportive of Wound Management
  • Characterization of PURION® Processed Dual Layer Chorion Allograft
  • Amniotic Membrane Allografts promote re-epithelialization in vitro via cJUN Mediated Mechanism
  • Adjunctive Dehydrated Human Amnion Chorion Membrane Usage for Pressure Injuries in the Post-Acute Care Setting
  • Reconstruction Following Mohs Surgery with a Placental Allograft: A Cost-Effectiveness Analysis

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com .

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

MDXG
The Conversation (0)
MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 21 st Annual Institutional Investor Conference Wednesday, May 29, 2024 Renaissance Minneapolis Hotel, The Depot... Keep Reading...
MIMEDX Announces First Quarter 2024 Operating and Financial Results

MIMEDX Announces First Quarter 2024 Operating and Financial Results

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024 , at 4:30 PM ET MiMedx Group, Inc. (Nasdaq: MDXG)... Keep Reading...
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share... Keep Reading...
Sona Nanotech

Sona Nanotech

Get access to more exclusive Nanotech Investing Stock profiles here Keep Reading...
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation: Date: Wednesday, June 12, 2024 Time:... Keep Reading...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two... Keep Reading...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk... Keep Reading...

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide... Keep Reading...

Latest Press Releases

Related News